Harnessing Csf-2 compartmentalized role on tissue resident phagocytes to uncouple anti-tumoral from pathological immunity induced by checkpoint inhibitors
利用 Csf-2 对组织驻留吞噬细胞的区室化作用,将抗肿瘤作用与检查点抑制剂诱导的病理免疫作用分开
基本信息
- 批准号:9228983
- 负责人:
- 金额:$ 38.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-02-06 至 2020-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdverse effectsAdverse eventAffectAgonistAntibodiesAntigen-Presenting CellsAntitumor ResponseCD8B1 geneCancer PatientCell Differentiation processCellsClinicalCutaneousCytotoxic T-Lymphocyte-Associated Protein 4Dendritic CellsDisease remissionDoseEastern Cooperative Oncology GroupEffector CellEndocrine systemEnterocolitisEnvironmentGastrointestinal tract structureGranulocyte-Macrophage Colony-Stimulating FactorHomeostasisImmuneImmune TargetingImmune checkpoint inhibitorImmune responseImmunityImmunosuppressionImmunosuppressive AgentsImpairmentIncidenceInjuryInstructionInterleukin-10IntestinesLaboratoriesLifeLightLiverLungLymphocyteMalignant neoplasm of ovaryMalignant neoplasm of prostateMediatingMetastatic MelanomaMolecularMononuclearMucous MembraneNormal tissue morphologyOutcomePathologicPathway interactionsPatientsPeripheralPhagocytesPhysiologicalPlayProductionRandomizedRegulatory T-LymphocyteRoleScienceSignal TransductionSiteSkinSolid NeoplasmSymbiosisT-LymphocyteTLR3 geneTherapeuticTherapeutic IndexTissuesToxic effectTretinoinTumor ImmunityTumor TissueUnresectableVaccinesadvanced diseaseantitumor effectarmbasecancer cellcytokinecytotoxicimmune checkpointimmune checkpoint blockadeimmunogenicimmunoregulationimprovedlung small cell carcinomalymph nodesmacrophagemalignant stomach neoplasmmelanomaneoplastic cellnovel strategiespatient subsetsphase II trialpreventpublic health relevanceresponsesuccesstumortumor microenvironment
项目摘要
DESCRIPTION (provided by applicant): There is now clear evidence that tumor tissues co-opt immune-checkpoint pathways to impair T cell ability to recognize and eliminate abnormal cancer cells. The clinical grade antibody, ipilimumab targeting the immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) was the first therapy to improve overall survival in patients with advanced melanoma. However, despite significant and long lasting remissions observed with CTLA4 blockade, responses remain limited to a subset of patients. In addition, although increasing doses of ipilimumab can significantly improve overall tumor responses, the therapeutic index of anti-CTLA4 mAb remains limited by the occurrence of immune-related adverse effects (irAE) that can be life threatening, unless promptly managed. Other irAE affect the skin, liver and the endocrine system. There is therefore an urgent need to develop novel strategies to not only increase, but to also uncouple, anti-tumor responses from unwanted immune related toxicities. Antitumor responses may be curtailed by alteration of T cell effector functions by an immunosuppressive tumor microenvironment despite the of CTLA4 blockade. T cell effector function is elicited in the lymph nodes (LN) and further modulated at local tissue sites by antigen presenting cells that include dendritic cells (DC) and macrophages (mph). Over the past decade, our group has been focusing on the mechanisms that control the homeostasis and function of DC and mph in normal and tumor tissues. Through this effort we discovered the instructive role played by the tissue environment in modulating DC and mph function. Specifically, we discovered that the cytokine GM-CSF, recently renamed Csf2, was produced by innate lymphocyte cells in the steady state gut in response to commensal signals to promote DC and mph production of retinoic acid and IL-10 that are necessary to induce intestinal T regulatory cell differentiation and expansion. These results extend previous studies by the Dranoff's laboratory showing that Csf2 drive DC and mph immunoregulation. Concomitantly, we and others have found that Csf2 controls the survival and function of cross-presenting cutaneous CD103+ DC and promotes vaccine CD8 cytotoxic immunity when combined with local tissue delivery of TLR agonists. Though on the one hand vaccine strategies utilizing Csf2-producing tumor cells have led to coordinated antitumor immune responses affecting substantial tumor destruction in patients, these successes has been tempered by the potential of Csf2 to promote tumor immunosuppressive effects. Our new results shed a new light into the mechanisms of action of Csf2-regulated immune responses and reveal that the dual regulatory and immunogenic role of Csf2 is dependent on both the tissue microenvironment in which it is produced and on the availability of DC activating signals. Our results also suggest that Csf2's compartmentalized role in tissue immunity could be exploited clinically to modulate CTLA4 outcome in cancer patients. Based on these results we hypothesize that "By harnessing Csf2 compartmentalized role on tissue phagocyte function we could uncouple anti-tumoral effects from unwanted immune related toxicity induced by immune checkpoint blockade".
描述(由申请人提供):现在有明确的证据表明,肿瘤组织同时进行了免疫检查途径,以损害T细胞识别和消除异常癌细胞的T细胞能力。临床级抗体,靶向免疫检查点细胞毒性T淋巴细胞相关的抗原4(CTLA4)的ipilimumab是提高晚期黑色素瘤患者总体生存率的第一种疗法。然而,尽管CTLA4封锁观察到了明显且持久的恢复,但反应仍然仅限于一部分患者。此外,尽管增加剂量的ipilimumab可以显着改善整体肿瘤反应,但抗CTLA4 MAB的治疗指数仍受到免疫相关的不良反应(IRAE)的限制,除非迅速管理,否则可能会危及生命。其他IRAE会影响皮肤,肝脏和内分泌系统。因此,迫切需要制定新的策略,不仅增加,而且还要与不需要的免疫相关毒性产生的抗肿瘤反应。 尽管CTLA4阻滞剂会通过免疫抑制性肿瘤微环境改变T细胞效应子功能,可以减少抗肿瘤反应。 T细胞效应的功能在淋巴结(LN)中引起,并通过包括树突状细胞(DC)和巨噬细胞(MPH)的抗原呈递细胞在局部组织部位进行了进一步调节。在过去的十年中,我们的小组一直集中在控制正常和肿瘤组织中DC和MPH的稳态和功能的机制上。通过这项努力,我们发现了组织环境在调节直流和MPH功能中起的启发性作用。具体而言,我们发现,最近更名为CSF2的细胞因子GM-CSF是由稳态肠道中的先天淋巴细胞细胞生成的,响应于共生信号,以促进视黄酸和MPH的产生,这些dc和MPH的产生是诱导无肠T调节性细胞分化和扩张所必需的。这些结果扩大了德拉诺夫实验室先前的研究,表明CSF2驱动直流和MPH免疫调节。同时,我们和其他人发现,CSF2控制交叉呈递皮肤CD103+ DC的存活和功能,并促进疫苗CD8 CD8细胞毒性免疫,与TLR激动剂的局部组织递送结合使用。尽管一方面利用CSF2产生的肿瘤细胞的疫苗策略导致了影响患者实质性肿瘤破坏的协调抗肿瘤免疫反应,但CSF2的潜力促进了这些成功,促进肿瘤免疫抑制作用。我们的新结果对CSF2调节的免疫反应的作用机理有了新的启示,并揭示了CSF2的双重调节和免疫原性作用取决于其产生的组织微环境以及DC激活信号的可用性。我们的结果还表明,可以在临床上利用CSF2在组织免疫中的分室作用,以调节癌症患者的CTLA4结果。基于这些结果,我们假设“通过利用CSF2在组织吞噬细胞功能上的CSF2分室作用,我们可以将抗肿瘤效应与免疫检查点阻断引起的不良免疫相关毒性取消抗肿瘤效应”。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MIRIAM MERAD其他文献
MIRIAM MERAD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MIRIAM MERAD', 18)}}的其他基金
Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalk
2型免疫:对上皮损伤的原始反应,形成骨髓和肺髓细胞串扰
- 批准号:
10577950 - 财政年份:2023
- 资助金额:
$ 38.77万 - 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
- 批准号:
8750561 - 财政年份:2014
- 资助金额:
$ 38.77万 - 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
- 批准号:
9095901 - 财政年份:2014
- 资助金额:
$ 38.77万 - 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
- 批准号:
9275540 - 财政年份:2014
- 资助金额:
$ 38.77万 - 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
- 批准号:
8896878 - 财政年份:2014
- 资助金额:
$ 38.77万 - 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
- 批准号:
9487761 - 财政年份:2014
- 资助金额:
$ 38.77万 - 项目类别:
Role of Mucosal DC Subsets in the Control of Influenza A Virus Immunity
粘膜 DC 亚群在控制甲型流感病毒免疫中的作用
- 批准号:
8294597 - 财政年份:2011
- 资助金额:
$ 38.77万 - 项目类别:
Characterizing a New Human Dendritic Cell Lineage and Its Role in LCH
人类新树突状细胞谱系的表征及其在 LCH 中的作用
- 批准号:
8597535 - 财政年份:2011
- 资助金额:
$ 38.77万 - 项目类别:
Systems Biology in Vaccination Post Autologous Hematopoietic Cell Transplant
自体造血细胞移植后疫苗接种中的系统生物学
- 批准号:
8307076 - 财政年份:2011
- 资助金额:
$ 38.77万 - 项目类别:
相似国自然基金
穿透性靶向胰腺癌内cDC1的纳米佐剂调控溶酶体逃逸促进放疗诱导ICD的机制研究
- 批准号:82303680
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多级改造的工程化外泌体自佐剂疫苗平台实现鼻上皮细胞感染拟态和粘膜递送的研究
- 批准号:32371440
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
展示PD-L1抗体的纳米锰佐剂联合放疗以诱导原位肿瘤疫苗的产生及其机制的探究
- 批准号:32371518
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
应用于冠状病毒广谱疫苗开发的新型全链式免疫增强型佐剂研究
- 批准号:82341036
- 批准年份:2023
- 资助金额:110 万元
- 项目类别:专项基金项目
相似海外基金
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer
开发针对胰腺癌的条件装甲 CAR 巨噬细胞疗法
- 批准号:
10710883 - 财政年份:2023
- 资助金额:
$ 38.77万 - 项目类别:
Validation of the joint-homing and drug delivery attributes of novel peptides in a mouse arthritis model
在小鼠关节炎模型中验证新型肽的关节归巢和药物递送特性
- 批准号:
10589192 - 财政年份:2023
- 资助金额:
$ 38.77万 - 项目类别:
Development of contrast agents to facilitate image-guided surgery
开发造影剂以促进图像引导手术
- 批准号:
10810184 - 财政年份:2023
- 资助金额:
$ 38.77万 - 项目类别:
A Mouse Model to Test the Effects of Gender-affirming Hormone Therapy on HIV Vaccine-induced Immune Responses
测试性别肯定激素疗法对 HIV 疫苗诱导的免疫反应影响的小鼠模型
- 批准号:
10748892 - 财政年份:2023
- 资助金额:
$ 38.77万 - 项目类别:
Multidomain Peptide Hydrogels as a Therapeutic Delivery Platform for Cancer Treatment
多域肽水凝胶作为癌症治疗的治疗传递平台
- 批准号:
10743144 - 财政年份:2023
- 资助金额:
$ 38.77万 - 项目类别: